Determination of serum visfatin levels in patients with Behcet’s disease: a case–control study

Nazarinia, M.A. and Habib Agahi, Z. and Aflaki, E. and Kamali Sarvestani, E. and Barkhordar, M. and Shenavandeh, S. (2016) Determination of serum visfatin levels in patients with Behcet’s disease: a case–control study. The Egyptian Rheumatologist, 38 (1).

Full text not available from this repository.


Abstract Aim of the work: Behc¸et’s disease (BD) is an inflammatory, systemic and chronic disorder with unknown etiology affecting multiple systems. Visfatin is a new adipokine with insulinmimetic properties and pro-inflammatory function. The serum visfatin levels were evaluated in BD patients to investigate its role in the pathogenesis and clinical manifestations of the disease. Patients and methods: Forty BD patients were recruited from the Behc¸et’s disease clinic at Shiraz University of Medical Sciences in southern Iran and 40 healthy control subjects of matching age, sex and body mass index (BMI) were also included. Serum visfatin level was measured using ELISA. Results: The 40 BD patients included 16 males and 24 females. Seventeen had active clinical manifestations; 16 with oral ulcer, 5 with genital ulcer, 6 with arthritis and 2 with uveitis. The mean age of the BD patients was 34.95 ± 9.6 years and mean BMI was 23.98 ± 4.44. There were no significant differences between cases (5.05 ± 3.05 ng/ml) and controls (4.72 ± 2.84 ng/ml) in the visfatin level (p = 0.61). The difference in the visfatin level between patients with active and inactive manifestations did not reach statistical significance (6.13 ± 3.20 and 4.25 ± 2.73, respectively; p = 0.07). There was no significant difference according to the gender of the patients or the presence of clinical manifestations.

Item Type: Article
Uncontrolled Keywords: Behc¸et’s disease; Serum visfatin; Disease activity
Subjects: WG Cardiovascular System
WH Hemic and Lymphatic System
Divisions: Faculty of Medicine
Depositing User: Users 1 not found.
Date Deposited: 19 Sep 2017 08:53
Last Modified: 19 Sep 2017 08:53

Actions (login required)

View Item View Item